Literature DB >> 32298205

Alemtuzumab: Rare serious adverse events of a high-efficacy drug.

Hans-Peter Hartung1, Jan Mares2, Michael H Barnett3.   

Abstract

Entities:  

Keywords:  Multiple sclerosis; adverse events; alemtuzumab

Year:  2020        PMID： 32298205     DOI： 10.1177/1352458520913277

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  7 in total

Review 1.  Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.

Authors:  Nik Krajnc; Gabriel Bsteh; Thomas Berger; Jan Mares; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2022-04-04       Impact factor: 6.088

2.  Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection.

Authors:  Daphne M Hullegie-Peelen; Marieke van der Zwan; Marian C Clahsen-van Groningen; Dana A M Mustafa; Sara J Baart; Marlies E J Reinders; Carla C Baan; Dennis A Hesselink
Journal:  Clin Pharmacol Ther       Date:  2022-03-08       Impact factor: 6.903

3.  A real-world study of alemtuzumab in a cohort of Italian patients.

Authors:  Cinzia Valeria Russo; Francesco Saccà; Jessica Frau; Pietro Annovazzi; Elisabetta Signoriello; Simona Bonavita; Roberta Grasso; Marinella Clerico; Cinzia Cordioli; Alice Laroni; Marco Capobianco; Valentina Torri Clerici; Arianna Sartori; Paola Cavalla; Giorgia Teresa Maniscalco; Sara La Gioia; Francesca Caleri; Alessia Giugno; Rosa Iodice; Antonio Carotenuto; Eleonora Cocco; Giuseppe Fenu; Mauro Zaffaroni; Damiano Baroncini; Giacomo Lus; Antonio Gallo; Stefania Federica De Mercanti; Caterina Lapucci; Valeria Di Francescantonio; Laura Brambilla; Maria Pia Sormani; Alessio Signori
Journal:  Eur J Neurol       Date:  2021-10-05       Impact factor: 6.288

4.  Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis.

Authors:  Dimitrios Tzanetakos; Marianthi Breza; John S Tzartos; Georgios Bontzos; Aigli G Vakrakou; Alexandros Dermentzoglou; Ilias Gkizis; Georgios Smoustopoulos; Maria-Eleptheria Evangelopoulos; Leonidas Stefanis; Costantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2022-10-08       Impact factor: 6.430

Review 5.  Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.

Authors:  Marc Pawlitzki; Uwe K Zettl; Tobias Ruck; Leoni Rolfes; Hans-Peter Hartung; Sven G Meuth
Journal:  EBioMedicine       Date:  2020-06-11       Impact factor: 8.143

6.  Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Report.

Authors:  Riccardo Garbo; Daniela Cutuli; Simone Lorenzut; Gian Luigi Gigli; Daniele Bagatto; Mariarosaria Valente
Journal:  Front Neurol       Date:  2021-12-08       Impact factor: 4.003

Review 7.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.